Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594990 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL16611012 | 0.92 | CYP2D6 (0.51) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL16720978 | 0.92 | CYP2D6 (0.45) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL16611088 | 0.92 | CYP2D6 (0.51) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL16720982 | 0.92 | CYP2D6 (0.45) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL16611014 | 0.92 | CYP2D6 (0.51) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL13236711 | 0.86 | CYP2D6 (0.41) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL13236709 | 0.86 | CYP2D6 (0.43) | CYP2D6CYP3A4CYP2C19CYP1A2LMNA | |
| SCHEMBL14778959 | 0.84 | CYP2D6 (0.59) | CYP2D6CYP3A4CYP2C19CYP1A2SMN1; SMN2 | |
| SCHEMBL6949043 | 0.83 | CYP2D6 (0.41) | CYP2D6CYP3A4CYP2C19CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3642195-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | NOVARTIS AG (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| EP-3423443-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | Novartis AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018234978-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1539697-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | Memory Pharmaceutical Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2004009552-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | CYP2D6 1183/4885CYP3A4 1193/4885CYP2C19 1172/4885 |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | KDM1A, KDM1B, KDM3A | CYP2D6 1548/4885CYP3A4 1490/4885CYP2C19 1139/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | CYP2D6 1183/4885CYP3A4 1193/4885CYP2C19 1172/4885 |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM2A | CYP2D6 1561/4885CYP3A4 1577/4885CYP2C19 1361/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | CYP2D6 452/4885CYP3A4 52/4885CYP2C19 236/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | CYP2D6 452/4885CYP3A4 52/4885CYP2C19 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.